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Oncogenes as the center of cancer research focused 
attention 30 years ago on signal transduction especially 
tyrosine phosphorylation.  Discovery that the Jun 
oncoprotein was a site-specific DNA binding protein 
demanded a connection of signaling abnormalities with 
transcriptional control [1].  The cytokine responsive 
Jak-STAT pathway, discovered through studying α -
interferon activation of STATs 1 and 2 by the Jak 
tyrosine kinases (Tyk2, Jak1, Jak2) was soon broadened 
to include the other five STATs [2]. The first 
description of STAT3 in 1994 [3] raised suspicion in 
the direction of cancer because IL-6 and EGF, already 
recognized to have cancer connections, were the 
originally recognized ligands that activated the STAT3 
homodimer.  
 
Less than a year later Richard Jove and colleagues 
made a convincing first link between STAT3 and 
oncogenesis [4]. Src-transformed cell lines all had 
persistently active STAT3 that was found to be 
required for Src-dependent oncogenic transformation 
of cultured cells [5,6].  Perhaps half or more of human 
tumors have long since been documented to contain 
persistently active STAT3 and human tumor cell lines 
depend on STAT3 for continued rapid growth and 
avoidance of apoptosis [7].  
 
So while a STAT3 cancer connection has been 
extensively documented, what precisely does STAT3 do 
to promote or sustain cancer?  Much work on STAT3 
gene targets supports an anti-apoptotic role for STAT3 
as well as a positive affect on cell growth.   
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Now, low and behold, STAT3 appears to be involved 
with the earliest recognized metabolic abnormality of 
cancer cells, energy derivation through glycolysis. 
Valeria Poli and a host of colleagues [8] have published 
a synthesis of previously established results plus many 
new experiments to provide convincing evidence that 
STAT3 transcriptional activity has an important role in 
establishing the addiction of tumor cells to glycolytic 
energy derivation and attendant glucose dependence ---- 
the Warburg effect [9, 10].   
 
Most of the new experiments [8] use mice in which the 
wild type STAT3 gene is replaced by a mutation 
originally produced in our laboratory.   We designed a 
STAT3 molecule we thought might provide constitutive 
activity by inserting cysteines in a relatively 
unstructured region of the SH2 domain [11].  Believing 
we had such a mutation because of high transcriptional 
signals without cytokine stimulation by the transfected 
mutant compared to wild type, Jackie Bromberg went 
on to show this mutant protein, named STAT3C, was 
capable of transforming cultured, partially transformed 
fibroblasts (NIH3T3 and rat 3Y1 cells).  These 
transformed cells grew into tumors in nude mice.  Many 
laboratories around the world have used the STAT3C 
construct that consistently augments transformation as 
we had found.   
 
However, we never obtained (attempts were made) to 
get a Y705F mutant of STAT3C and did not 
demonstrate therefore that the mutant required 
phosphorylation  of Y705  just as does the wild  type  in  
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has corrected our error. STAT3C indeed requires Y705 
phosphorylation to be active [12].  Shaw and Li showed 
that the STAT3C phosphodimer binds DNA better than 
the wild type, a characteristic that allows it to remain 
phosphorylated in the nucleus for a longer period of 
time after activation.  Thus STAT3C is simply what the 
bacterial geneticists were calling an “up” mutation 
several decades ago.  There is still no dispute that 
STAT3C can act as a cooperating oncogene. And 
Demaria et al. [8] show definitive effects in MEFs 
(mouse embryo fibroblasts) of STAT3C/C compared to 
STAT3 WT including presence in the cell nucleus 
without a known cytokine activation, longer nuclear 
retention after IL-6 treatment, faster growth, and 
resistance to apoptosis induced by four different agents.  
The activity of STAT3C is presumably due to the low 
level of STAT3 activation of cells growing in normal 
serum containing medium, a situation proven earlier by 
blocking phosphatase activity in the absence of a 
cytokine ligand and observing STAT1 and STAT3 
DNA binding [13,14]. 
 
The Warburg type tumor metabolism in STAT3C/C 
cells depends on an increase in levels of HIF1 α that is 
at least partly due to increased STAT3 dependent 
transcription shown earlier by Niu et al. [15] with 
further new evidence in STAT3
C/C MEFs.  And HIF1α 
increases transcription of all known glycolytic enzymes.  
STAT3c/c activity also increases mRNA for a set of 
proteins, including PDK-l (pyruvate dehydrogenase 
kinase 1) which blocks the shuttling of pyruvate into the 
citric acid cycle in mitochondria sending it into the 
glycolytic pathway with resulting increased lactic acid 
production. With the increased dependence on 
glycolysis STAT3
C/C cells require high glucose to avoid 
apoptosis. A decreased mitochondrial oxidative 
phosphorylation attendant to presence of STAT3
C/C 
likely depends on a lowered amount of mRNA for 
mitochondrial proteins, e.g. ATP synthase, for the G 
subunit of the mitochondrial FO complex, for fumarate 
hydratase. 
 
The authors discuss the recent findings of Andy Larner 
and David Levy [16,17] that establish the presence of 
non-tyrosine phosphorylated STAT3 in mitochondria 
that plays a required role in transformation by the Ras 
oncogene.  It is the phosphorylation of serine 727, 
which in the nucleus is required for maximal 
transcriptional stimulation, that is important in both the 
Ras transformation of cells as well as in the maximal 
functioning of mitochondrial oxidative phosphorylation.   
 
A major point made in the Demaria et al. paper is that 
the metabolic effect brought about by phosphorylating 
tyrosine 705 activates STAT3 in the cell nucleus (as 
must occur at a low level in STAT3
C/C) is a separate set 
of events from the serine 727 phosphorylation inside the 
mitochondria.  Thus there is no contradiction between 
the two sets of findings but emphasizes STAT3 has 
multiple roles in cell transformation. The powerful 
message of the newest results is that STAT3 is involved 
in the time-honored characteristic of cancer cells, 
dependence on glycolytic energy derivation.   
 
REFERENCES 
 
l. Vogt PK. Oncogene. 2001; 20:2365‐2377. 
2. Darnell JE, Jr.  Science. 1997; 277:1630‐1635. 
3. Zhong Z, Wen Z, and Darnell JE, Jr.   Science. 1994;  264:95‐98. 
4.  Yu  CL,  Meyer  DJ,  Campbell  GS,  Larner  AC,  Carter‐Su  C, 
Schwartz J, and Jove R. Science. 1995; 269:81‐83. 
5. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Grott RP, 
and Jove R. Mol. Cell. Biol. 1998; 18:2545‐2552. 
6. Bromberg JF, Horvath CM, Besser D, Lathem WW, and Darnell 
JE, Jr. Mol. Cell. Biol. 1998;18: 2553‐2558. 
7. Yu H and Jove R. Nature Rev. Cancer. 2004; 4:97‐105. 
8. Demaria M et al.  Aging. 2010; 2: 823‐842 . 
9. Warburg O. Science. 1956; 124:269‐270. 
10. Warburg O. Science. 1956; 123:309‐314.    
11. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell 
RG, Albanese C, and Darnell JE Jr. Cell. 1999; 98:295‐303. 
12. Li L and Shaw PE.  J. Biol. Chem. 2006; 281:33172‐33181. 
13. Carallo M et al.  J. Biol. Chem. 1999; 274:17580‐17586. 
14. David M, Grimley PM, Finbloom DS, and Larner AC.  Mol. 
Cell. Biol. 1993; 13:7515‐7521. 
15. Niu G et al.  Mol. Cancer Res. 2008; 6:1099‐1105. 
16. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, 
and Levy DE. Science. 2009; 324:1713‐1716. 
17. Wegrzyn J et al.  Science. 2009; 323:793‐797. 
   
www.impactaging.com                 891                                    AGING,   December 2010, Vol.2 No.12